EGFR and neoplasm: Notably, the analysis with The Cancer Genome Atlas (TCGA) database to investigate the clinical relevance of ChAT expression in EGFR-mutant NSCLC patients showed that patients with high ChAT levels were associated with a reduction in overall survival (Supplemental Figure 7B), suggesting there may exist an intrinsic aggressiveness in tumor cells expressing high levels of ChAT.